Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of mirogabalin 15 mg tablet vs OD tablet in healthy Japanese males
jRCT1080225061Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of mirogabalin in Neuralgia (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Started Feb 2020; status: completed.
02
Drugs
mirogabalin
03
Conditions
Neuralgia
Beyond the preview
Go deeper on jRCT1080225061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225061.